PDS Biotechnology (PDSB) Announces Workforce Reduction, COO Removed

What Happened PDS Biotechnology Corporation (PDSB) announced a reduction in force approved by its board on August 6, 2026, and implemented with affected employees notified on August 21, 2026. The action is intended to align operating expenses with the company’s strategic focus on advancing PDS0301. The reduction is expected to affect approximately 36% of the workforce and to be substantially completed during the third quarter of 2026. PDSB expects to record a one-time, cash charge of about $842,000 in Q3 2026 for employee separation benefits (severance and related benefits). Separately, on August 21, 2026 the company terminated Chief Operating Officer Stephan Toutain without cause; he is eligible for severance under his employment agreement (12 months base salary paid on payroll dates plus company contributions toward COBRA for up to 12 months) upon execution of a separation agreement and release.

Key Details

• Board approved reduction in force: August 6, 2026; notifications delivered August 21, 2026.
• Estimated workforce impact: ~36% of employees; substantially completed in Q3 2026.
• Estimated one-time charge: approximately $842,000, recognized as cash expenditures in Q3 2026.
• COO change: Stephan Toutain terminated without cause on August 21, 2026; severance = 12 months base pay + COBRA contributions, contingent on separation agreement and release. The filing does not state whether the COO severance is included in the $842,000 estimate.

Why It Matters This filing signals a meaningful cost-reduction move to prioritize resources toward advancing PDS0301. Investors should note the immediate cash impact: a one-time Q3 charge of ~$842,000 and potential additional costs the company says could arise. The removal of the COO is a material executive change that carries contractual severance obligations; leadership changes and a substantial headcount reduction may affect operations and execution in the near term.